Asthma
📧 Sign up to get email alerts when something new happens for Asthma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-26EMA Authorised: Tezspire (tezepelumab) — AstraZeneca AB
Authorised status for Tezspire (tezepelumab) by AstraZeneca AB for asthma and sinusitis in the EMA, indicating market authorisation.
-
EMA approval · 2026-08-19EMA Authorised: Nucala (Mepolizumab) — GlaxoSmithKline Trading Services Limited
EMA has authorised Nucala (mepolizumab) for asthma, confirming regulatory approval in the European Union.
-
EMA approval · 2026-08-18EMA Authorised: Dupixent (dupilumab) — Sanofi Winthrop Industrie
The EMA has authorised Dupixent (dupilumab) for multiple indications including atopic dermatitis, prurigo, esophageal diseases, asthma, and …
-
EMA approval · 2026-08-13EMA Authorised: Exdensur (depemokimab) — GlaxoSmithKline Trading Services Limited
EMA authorised Exdensur (depemokimab) for asthma and nasal polyps under GlaxoSmithKline Trading Services Limited.
-
EMA approval · 2026-07-22EMA Authorised: Nucala (Mepolizumab) — GlaxoSmithKline Trading Services Limited
Authorisation of Nucala (mepolizumab) for asthma by EMA, confirming its market approval in the European Union.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-06-25EMA Authorised: Tezspire (tezepelumab) — AstraZeneca AB
The EMA has authorised Tezspire (tezepelumab) by AstraZeneca AB for therapeutic use in asthma and sinusitis.
-
EMA approval · 2026-06-16EMA Authorised: Nucala (Mepolizumab) — GlaxoSmithKline Trading Services Limited
Authorised status for Nucala (mepolizumab) by EMA for asthma.
-
EMA approval · 2026-06-08EMA Authorised: Xolair (omalizumab) — Novartis Europharm Limited
EMA has authorised Xolair (omalizumab) for indications including asthma, urticaria, and rhinitis, under the MAH Novartis Europharm Limited.
-
EMA approval · 2026-04-20EMA Authorised: Dupixent (dupilumab) — Sanofi Winthrop Industrie
The EMA authorised Dupixent (dupilumab) for multiple EU indications, including atopic dermatitis, prurigo nodularis, eosinophilic esophagiti…
-
EMA approval · 2026-03-12EMA Authorised: Exdensur (depemokimab) — GlaxoSmithKline Trading Services Limited
The EMA authorised Exdensur (depemokimab) for treatment indications in asthma and nasal polyps. Decision date 12 February 2026.
-
EMA approval · 2026-03-09EMA Authorised: Nucala (Mepolizumab) — GlaxoSmithKline Trading Services Limited
The EMA has authorised Nucala (mepolizumab) for asthma, with GlaxoSmithKline Trading Services Limited listed as the marketing authorisation …
-
FDA approval · 2026-01-12FDA Approved: FLUTICASONE PROPIONATE AND SALMETEROL — Original Application (Lannett Company, Inc.)
FDA approved a generic version of the fluticasone propionate and salmeterol inhalation product (Lannett) under an original ANDA, for mainten…
-
EMA approval · 2025-12-16EMA Authorised: Seffalair Spiromax (fluticasone propionate;salmeterol xinafoate) — Teva B.V.
The EMA has authorised Seffalair Spiromax, a fixed-dose inhaler containing fluticasone propionate and salmeterol xinafoate, for asthma; Teva…
-
FDA approval · 2025-12-01FDA Approved: ALBUTEROL SULFATE INHALATION — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal's albuterol sulfate inhalation as a generic inhalation product under ANDA 211600 for relief of bronchospasm in reversibl…
-
EMA approval · 2025-11-20EMA Authorised: Enerzair Breezhaler (indacaterol;glycopyrronium bromide;mometasone) — Novartis Europharm Limited
EMA authorised Enerzair Breezhaler, a fixed-dose inhaler combining indacaterol, glycopyrronium bromide, and mometasone, for asthma under Nov…
-
EMA approval · 2025-11-20EMA Authorised: Atectura Breezhaler (indacaterol acetate;mometasone furoate) — Novartis Europharm Limited
The EMA authorised Atectura Breezhaler, a combination inhaler containing indacaterol acetate and mometasone furoate, for asthma.
-
EMA approval · 2025-11-18EMA Authorised: Omlyclo (omalizumab) — Celltrion Healthcare Hungary Kft.
EMA has authorised Omlyclo (omalizumab) by Celltrion Healthcare Hungary Kft. for asthma and urticaria.
-
EMA approval · 2025-10-30EMA Authorised: Zimbus Breezhaler (glycopyrronium bromide;Indacaterol (acetate);mometasone furoate) — Novartis Europharm Limited
The EMA authorised Zimbus Breezhaler, a fixed-dose inhaler containing glycopyrronium bromide, indacaterol (acetate), and mometasone furoate …
-
EMA approval · 2025-10-22EMA Authorised: Tezspire (tezepelumab) — AstraZeneca AB
The European Medicines Agency authorised Tezspire (tezepelumab) by AstraZeneca AB for the treatment of asthma and sinusitis in the EU.
-
FDA approval · 2025-10-17FDA Approved: TEZSPIRE — Supplemental Application (Amgen Inc)
FDA approved a supplemental application for TEZSPIRE (TEZEPELUMAB-EKKO) from Amgen Inc.
-
EMA approval · 2025-10-07EMA Authorised: Bemrist Breezhaler (indacaterol;mometasone furoate) — Novartis Europharm Limited
The EMA authorised Bemrist Breezhaler, a fixed-dose inhaler combining indacaterol and mometasone furoate, for asthma; the marketing authoriz…
-
FDA approval · 2025-09-30FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Montelukast Sodium by Amneal Pharmaceuticals LLC. This approval relates to an updated labeling o…
-
FDA approval · 2025-09-26FDA Approved: QVAR REDIHALER — Supplemental Application (Teva Respiratory, LLC)
FDA approved Teva's supplemental application for QVAR REDIHALER (beclomethasone dipropionate HFA), expanding the approved QVAR inhaled corti…
-
FDA approval · 2025-07-01FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approved a supplemental application for montelukast sodium from Ajanta Pharma USA Inc., updating the approved ANDA product via a supplem…
-
FDA approval · 2025-07-01FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Ajanta Pharma USA Inc.)
The FDA approved a supplemental application for Montelukast Sodium from Ajanta Pharma USA Inc., under an ANDA.